Morse College is a vibrant community. We would love to count you among us. The Fellows meet a few times per semester at the Head of College’s house, to interact with friends from all parts of the University and from the broader community. Many play the role of Advisor for a student or two. We extend invitations to student functions such as performances and college-wide social events, welcome participation at intramural sports, provide dining privileges in the college at lunch or dinner, all so you can meet with students, faculty and friends. Please join us - we welcome you!
Biotech Executive, CEO
Mark Velleca joined G1 Therapeutics as CEO in May 2014. Previously, he was a founder and SVP of CGI Pharmaceuticals, where he guided the company from its inception (as a Yale incubated start-up) through its establishment as a drug discovery company that brought multiple drug candidates into clinical trials. When CGI was acquired by Gilead in 2010, Dr. Velleca served as a senior advisor to Gilead. He helped the company build its oncology pipeline through prioritization of internal programs, academic partnerships, in-licensing, technology deals and acquisitions. He most recently served as EVP at The Leukemia & Lymphoma Society. Earlier in his career, he was an attending physician at Yale New Haven Hospital and on the faculty of Yale Medical School. He earned a B.S. in biology Cum Laude from Yale and an M.D. and Ph.D. in neuroscience from Washington University in St. Louis. He has served on the board of directors of BioMarker Strategies, a Johns Hopkins-founded oncology diagnostics company, as well as the scientific advisory boards of Intellikine (a UCSF-founded drug discovery company that was acquired by Takeda in 2011) and BioRelix, a Yale-founded antibiotics drug discovery company.
Dr. Velleca is happy to explore discussions regarding entrepreneurship,drug discovery and development, biotechnology, precision medicine, genomics, healthcare policy, and health IT.